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Uniting the neuro developmental 
and immunological hypotheses: 
Neuregulin 1 receptor ErbB and 
Toll-like receptor activation in first-
episode schizophrenia
Szabolcs Kéri1,2,3, Csilla Szabó1 & Oguz Kelemen4
Current pathophysiological models of schizophrenia focus on neurodevelopmental and immunological 
mechanisms. We investigated a molecular pathway traditionally linked to the neurodevelopmental 
hypothesis (neuregulin 1 - ErbB), and pathogen-associated pattern recognition receptors associated 
with the immune hypothesis (Toll-like receptors, TLRs). We recruited 42 first-episode, drug-naïve 
patients with schizophrenia and 42 matched healthy control subjects. In monocytes TLR4/TLR5 and 
ErbB expressions were measured with flow-cytometry. Pro-inflammatory cytokines (IL-1β, IL-6, 
and TNF-α) and the anti-inflammatory cytokine IL-10 were determined following the stimulation 
of TLR4/TLR5 and ErbB. Results revealed increased TLR4/TLR5 and decreased ErbB4 expression in 
schizophrenia relative to the control subjects. The expression of ErbB2 and ErbB3 receptors was 
unaltered in schizophrenia. TLR4 stimulation resulted in lower pro-inflammatory cytokine production 
in schizophrenia compared to the control levels, whereas the stimulation of ErbB by neuregulin 1 
led to higher pro-inflammatory cytokine levels in patients with schizophrenia relative to the control 
group. In healthy controls, ErbB activation was associated with a marked production of IL-10, which 
was dampened in schizophrenia. These results indicate that the stimulation of TLR4 and ErbB induces 
opposite pro-inflammatory cytokine responses in schizophrenia.
The etiology and pathophysiology of schizophrenia are one of the most multifaceted and controversial areas of 
research into neuropsychiatric disorders. Beyond the classic neurodevelopmental hypothesis, supposing an inter-
action between inherited genetic factors and environmental insults1–3, there is a renewed and emerging interest 
regarding the putatively underlying immunological alterations in schizophrenia4–6. However, the neurodevelop-
mental and immunological hypotheses are not mutually exclusive7. There is evidence that immunological and 
inflammatory mechanisms play a substantial role in early and late neurodevelopmental processes, as well as in the 
regulation of neurotransmission and synaptic plasticity8–10.
Several “historical candidate genes” of schizophrenia discovered in the past decades have been shown to be 
related to neurodevelopment and synaptic plasticity, but, disappointingly, new generations of genome-wide asso-
ciations studies failed to replicate most of these findings11, 12. New molecular genetic data, based on genome-wide 
association studies with better statistical power, suggest that major histocompatibility complex class I (MHC-I) 
molecules may form a bridge between genetic predisposition, immunological mechanisms, and environmental 
risk factors (e.g., maternal infection, obstetric complication, and stress) by regulating neurite growth, synapse 
formation, and activity-dependent synaptic tuning in the brain13. Another new candidate is the complement sys-
tem, a complex network of more than 30 plasma proteins facilitating antigen-antibody interactions and coating 
pathogens, which are also implicated in synaptic pruning in the brain14, 15.
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A somewhat neglected observation is that the products of some “historical candidate genes” also have an 
impact on immune functions. A notable example is the profoundly characterized molecule neuregulin 1 (NRG1) 
and its ErbB receptors (ErbB4 and ErbB2/ErbB3 complex)16–21. A timely and detailed review and a meta-analysis 
by Mostaid et al.16, 22 demonstrated that, despite the fact that whole-genome association studies did not con-
firm a link between NRG1/ErbB genes and schizophrenia, there is substantial evidence from other types of pre-
clinical and clinical studies that NRG1 may be relevant in the pathophysiology of schizophrenia by regulating 
not only synapse formation but the balance between excitatory (glutamatergic) and inhibitory (GABA-ergic) 
neurotransmission.
In addition to these neuronal effects, NRG1 can modulate the functions of peripheral immune cells. Sei 
et al.23 demonstrated that NRG1-induced cell migration of B lymphoblasts is decreased in schizophrenia, which 
is at least partly mediated by impaired AKT signaling stimulated by the tyrosine-kinase receptor ErbB4. The 
authors hypothesized that this phenomenon might be a peripheral immunological marker of central nervous 
system developmental anomalies23. ErbB3, but not ErbB2, mRNA levels were significantly reduced in the lymph-
oblasts of schizophrenia patients, and it was not associated with the ErbB4 risk haplotype24. We showed that 
impaired NRG1-induced B cell activation correlates with weak physiological habituation of arousal and paranoid 
ideas25, abnormal gating of perceptual information26, and decreased hippocampal volume in schizophrenia27. 
Furthermore, additional evidence from animal and human studies suggests that NRG1 may be a key factor in the 
interplay of neurodevelopment, synaptic plasticity, glutamatergic/GABA-ergic neurotransmission, and immuno-
logical mechanisms in schizophrenia28–35.
Recently, Crisafulli et al.36 conducted a thorough molecular network analysis and found that 60 
single-nucleotide polymorphisms of 30 schizophrenia-associated genes are related to pathways of neurodevel-
opment, apoptosis, vesicle traffic, immune response, and the mitogen-activated protein kinase (MAPK) pathway, 
a characteristic pattern of Toll-like receptor (TLR) cascade. TLRs are implicated in the first-line detection of 
pathogens and danger-related signals indicating tissue damage37–40. However, the functional relationship between 
NRG1/ErbB and TLRs has not been elucidated.
TLRs can be found on the membrane of macrophages and other immune cells (TLR1, TLR2, TLR4, TLR5, 
TLR6, and TLR11 are inserted into cell membranes; TLR3, TLR7, TLR8, and TLR9 are localized to intracellu-
lar compartments). The first element of the TLR signaling pathway is the cytoplasmic Toll/Interleukin-1 (IL-1) 
receptor (TIR) domain, which is linked to an adaptor, MyD8837–40. An analysis of the statistical epistatic network 
of NRG1 in clinical studies of schizophrenia indicated its relationship with IL-1β16, which may be an important 
link to TLR signaling.
TLRs do not exclusively participate in peripheral immunological functions. For example, TLR3 and TLR4 
have an impact on neurodevelopment, neuronal survival, and plasticity by regulating the interactions between 
the immune system and neurons in the developing brain10, 41. Consistent with this function, several studies 
have demonstrated an altered expression and activation of TLRs in schizophrenia in immune cells and neu-
ronal elements42–46. Recently, we demonstrated up-regulated TLR4 and TLR5 on monocytes and lymphocytes of 
drug-naïve schizophrenia patients; TLR4, but not TLR5, alterations were normalized by antipsychotic treatment47. 
In the drug-naïve state, a higher expression of TLR4 was associated with worse cognitive functions, indicating 
that abnormal peripheral TLR expression may be linked to central nervous system processes in schizophrenia47.
The results discussed above raise the possibility that the NRG1/ErbB and the TLR systems may interact in 
schizophrenia. However, this hypothesis has not been investigated empirically. Therefore, in the present study, 
we specifically focused on the expression and activation of TLRs and ErbB on the monocytes of 42 drug-naïve, 
first-episode schizophrenia patients. A considerable amount of data from previous studies suggest that TLR4 may 
be especially important in the pathogenesis of schizophrenia and other neuropsychiatric conditions46, and mono-
cytes are dominantly affected in schizophrenia44, 47. TLR5 served as a control to test the specificity of TLR4-related 
changes.
In addition to receptor expression, we investigated the production of proinflammatory (IL-1β, IL-6, and 
TNF-α) and anti-inflammatory (IL-10) cytokines by monocytes after stimulation with TLR4/TLR5 ligands (bac-
terial lipopolysaccharides (LPS) and flagellin, respectively) and NRG1. We hypothesized an abnormal expression 
and activation of TLRs and ErbB in patients with schizophrenia relative to the control subjects44, 47, 48.
Results
Expression of TLRs and ErbB. There was a significant difference between patients with schizophrenia and 
healthy control participants in the expression (mean fluorescent intensity (MFI) as measured by flow cytom-
etry) of TLRs and ErbB4: we observed an increased expression of TLR4 (F(1,82) = 30.21, p < 0.001; η2 = 0.27) 
and TLR5 (F(1,82) = 11.27, p < 0.005; η2 = 0.12) in patents with schizophrenia relative to the control subjects, 
whereas in the case of ErbB4, the opposite effect was found (decreased expression in schizophrenia compared to 
the controls) (F(1,82) = 31.30, p < 0.001; η2 = 0.28). There was no significant between-group difference for ErbB2 
and ErbB3 (Fig. 1).
Cytokine production following TLR and ErbB4 stimulation. There was a significant difference 
between patients with schizophrenia and healthy controls in cytokine production (main effect of group in the 
ANOVA: F(1,82) = 4.35, p < 0.05; η2 = 0.05). However, the difference between patients and controls was mod-
ulated by the type of receptor stimulation (TLR4/TLR5 and ErbB ligands) (two-way interaction between group 
and stimulation type in the ANOVA: F(2,164) = 33.34, p < 0.001; η2 = 0.29). Critically, the difference between 
patients and controls was modulated by the interaction of stimulation type and different cytokines (IL-1β, IL-6, 
TNF-α, and IL-10) (three-way interaction between group, stimulation type, and cytokines in the ANOVA: 
F(6,492) = 11.55, p < 0.001; η2 = 0.12).
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The three-way interaction among experimental group, stimulation type, and cytokines was further analyzed 
with Tukey HSD tests. In the case of TLR4 stimulation, there were significantly weaker IL-1β, IL-6, and TNF-α 
responses in schizophrenia relative to the control subjects (p < 0.01), whereas IL-10 production was intact 
(p > 0.5). In the case of TLR5 stimulations, there were no significant differences between patients and controls 
(p > 0.5) (Fig. 2).
Finally, in the case of ErbB stimulation by NRG1, we observed a very different pattern of cytokine secretion. 
For IL-1β, IL-6 and TNF-α, we observed a significantly higher response in schizophrenia patients than in control 
Figure 1. Mean fluorescent intensity (MFI) values for TLRs and ErbB in patients with schizophrenia (SCZ, 
n = 42) and healthy control subjects (CONT, n = 42) as measured in monocytes by flow cytometry. Error bars 
indicate 95% confidence intervals. *Significant between-group differences, Tukey HSD, p < 0.01.
Figure 2. Mean concentration of cytokines following TLR and ErbB4 stimulation in patients with 
schizophrenia (SCZ, n = 42) and healthy control subjects (CONT, n = 42). Error bars indicate 95% confidence 
intervals. *Significant between-group differences, Tukey HSD, p < 0.05.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 4147  | DOI:10.1038/s41598-017-03736-3
subjects (p < 0.05). In contrast, IL-10 response was significantly dampened in schizophrenia as compared to the 
control values (p < 0.01) (Fig. 2).
Potential confounding factors and clinical symptoms. We performed a separate series of covari-
ance analyses (ANCOVAs) in which smoking, blood cortisol levels reflecting general stress response, body mass 
index, waist-to-hip ratio, the duration of untreated psychosis, and the PANSS scores were included in the above 
described ANOVAs as co-variants. The results remained the same, suggesting that these variables do not account 
for the between-group differences. Similarly, there was no effect of age and sex (p > 0.2).
Discussion
The findings of the present study indicate that the activation of monocytes of schizophrenia patients is 
receptor-dependent. In accordance with previous studies44, 47, TLR4 displayed an increased expression, and 
the stimulation of these receptors resulted in a lower production of pro-inflammatory cytokines as compared 
to that observed in healthy control participants. The key and novel finding of the study was that ErbB recep-
tors were characterized by the opposite pattern of expression and activation: there was a lower expression of 
ErbB4 in schizophrenia relative to controls, but NRG1-induced activation of ErbB receptors led to an enhanced 
pro-inflammatory cytokine response. Interestingly, the activation of ErbB resulted in a higher production of 
the anti-inflammatory cytokine IL-10 in healthy individuals as compared to TLR-related IL-10 responses, 
and this ErbB-dependent IL-10 release was much less dominant in schizophrenia. This suggests a weakened 
NRG1-dependent anti-inflammatory response in schizophrenia.
Although we did not find an altered expression of ErbB2/ErbB3 receptors in schizophrenia, it cannot be 
excluded that the observed cytokine profile following NRG1 stimulation is at least partially due to the abnormal 
activation of ErbB2/ErbB3 receptors, and not only ErbB4 with reduced expression is responsible for the effect. 
Indeed, recent evidence indicates that ErbB3 plays an important role in the modulation of monocyte responses49. 
The role of different ErbB receptors must be clarified by further studies. Similarly, a key issue is how TLR and 
ErbB activation might modulate cytokine production in the brain.
Several previous studies found an increased expression of some splicing variants of ErbB4 in the dorsolat-
eral prefrontal cortex of schizophrenia patients21, 50–52, as well as in peripheral lymphoblastoid cells24. This is in 
contrast with our present findings indicating a decreased expression of ErbB4 in monocytes. Different methods 
(measuring receptor protein expression by flow cytometry in this study vs. mRNA splice variants in other stud-
ies), distinct cell lines (monocytes in this study vs. neurons from postmortem brains and lymphoblastoid cells 
in other studies), medication status, and illness duration might account for the differences. In addition, ErbB4 
expression is influenced by schizophrenia risk haplotypes, and individuals homozygous for the non-risk haplo-
type exhibit undetectable levels of ErbB4 in lymphoblastoid cells24. We did not evaluate ErbB4 haplotypes in our 
participants.
By using LPS and polyI:C stimulation, Muller et al.44 found higher TLR4 and TLR3, but not TLR2, expression 
in monocytes of patients with schizophrenia, which was replicated and extended in an independent sample of 
drug-naïve patients47. Muller et al.44 also demonstrated a weakened intracellular IL-1β response in the same 
patients, which suggests a blunted function and a compensatory up-regulation of TLRs. Monocyte hypofunction 
may lead to a reduced clearance of pathogens and a consequent low-grade inflammation5, 53, 54, which may have 
a negative impact on cognition and cardiovascular health of the patients. The present data suggest that blunted 
monocyte function is not a general phenomenon: in the case of ErbB4, we observed an enhanced response 
together with a down-regulation of the receptor. Moreover, altered monocyte activation was confined to a specific 
pattern recognition receptor, namely, TLR4. Although TLR5 was also up-regulated in schizophrenia, the stimu-
lation of this receptor resulted in a pro-inflammatory cytokine response comparable to that measured in control 
subjects. The dissociation between TLR4 and TLR5 response might be attributed to their partially distinct intra-
cellular pathways and compartmentalization: TLR4 is linked to TRIF (TIR-domain-containing adapter-inducing 
interferon-β)/TRAM (translocating chain-associated membrane) protein (in addition to the classic MyD88 path-
way), whereas TLR5 activates IRAK4 via MyD8855–57. This hypothesis should be tested by future studies.
The convergence point of TLR and ErbB signaling may be nuclear factor κB (NF-κB), which regulates the 
expression of genes encoding pro-inflammatory proteins (cyclooxygenase 2, inducible nitric oxide synthase, and 
cytokines such as IL-1β, IL-6, and TNF-α)58. However, the effect of NRG1 is thought to be anti-inflammatory. In 
cultured microglia and macrophages, Mencel et al.59 demonstrated that treatment with NRG1 produced a 33% 
decrease in TNF-α levels and an 88% decrease in IL-6 levels. NRG1 may have an anti-inflammatory and neuro-
protective function via the up-regulation of α7 nicotinic acetylcholine receptor, a key component not only in neu-
rotransmission and schizophrenia, but also in cholinergic anti-inflammatory responses60. Tynyakov-Samra et al.61 
found reduced levels of ErbB4 in monocytes and lymphocytes of patients with multiple sclerosis, characterized 
by neuro-inflammation and oligodendroglia dysfunction. The reduced production of IL-10 following ErbB stim-
ulation in schizophrenia suggests an enhanced inflammatory phenotype and a dysfunctional anti-inflammatory 
effect of NRG162.
The present study is not without limitations. First, cytokine levels were measured only after TLR/ErbB stim-
ulation. However, we observed different cytokine profiles following TLR and ErbB stimulation, which is against 
the possibility that our findings reflect baseline characteristics and that these immunological changes would be 
apparent without stimulation. Second, we did not investigate neuregulin 1-beta, which is a predominant form 
in the brain16. Third, it has not been explored how antipsychotics may modulate TLR/ErbB expression and acti-
vation. Regarding TLR4/TLR5, it has been demonstrated that antipsychotics reduce receptor expression47. We 
focused our current investigations on TLR4/TLR5 because in a previous study we did not find altered expressions 
of other TLRs47.
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The alterations of TLR4 is not specific for schizophrenia. Rather, it might be a common feature of stress-related 
and developmental neuropsychiatric disorders, including schizophrenia, autism, major depressive disorder, and 
bipolar disorder45, 46, 63–65. The exact mechanism of TLR4 activation in these disorders is not known. A testable 
hypothesis focuses on stress-related increases in intestinal permeability (“leaky gut”), which results in the trans-
location of enteral bacteria to the submucosa where they consequently activate TLRs66–68.
Law et al.24 proposed that the NRG1-ErbB4 signaling system may be a potential therapeutic target for schiz-
ophrenia with a special reference to phosphoinositide 3-kinase-p110δ inhibitors. Similar suggestions have been 
raised in relation to TLR445. Our data indicate that a combined approach targeting both ErbB4 and TLR4 recep-
tors may have a higher chance to achieve clinically significant effectiveness. However, there are several open 
questions. First, future research should delineate how TLRs and ErbB interact in the brain. Another important 
question is the potential link between peripheral immunological alterations and the clinical course of schizo-
phrenia. The clarification of these issues might markedly improve our chance to uncover new biomarkers and 
therapeutic targets for schizophrenia.
Methods
Participants and clinical assessment. Forty-two drug-naïve patients with first-episode schizophrenia 
and 42 healthy control subjects matched for age, gender, and education participated in the study at the National 
Institute of Psychiatry and Addictions, Budapest, Hungary (Table 1). The mean duration of untreated psychosis 
was 7.6 months (SD = 4.0). For clinical assessment, we used the Structured Clinical Interview for DSM-IV Axis 
I Disorders, Clinician Version (SCID-CV)69, and the Positive and Negative Syndrome Scale (PANSS)70 (Table 1). 
Overall functioning was assessed with the Global Assessment of Functioning (GAF) scale69. The exclusion criteria 
were history of neurological disorders, head injury, inflammatory diseases or current infections, and psychoactive 
substance misuse. The patients and controls did not receive anti-inflammatory medications at least for 3 months 
before testing.
The study was done in accordance with the Declaration of Helsinki. All participants gave written informed 
consent and the study was approved by the appropriate ethics board (Egészségügyi Tudományos Tanács 
– TUKEB).
Cell isolation and flow cytometry. First, we determined leukocyte counts (LH750 instrument, 
BeckmanCoulter, Hialeah, FL, USA). There were normal leukocyte ranges in patients with schizophrenia and 
control individuals (cells × 109/L; neutrophils: 1.6–8.1, monocytes: 0.1–1.1, lymphocytes: 0.9–4.9), and there was 
no significant difference between the two groups (p > 0.3).
The technical details of the protocol were described previously47, 64. We obtained peripheral blood (20 mL) 
from the cubital vein (EDTA tubes). Mononuclear cells were isolated by density gradient centrifugation (900 × g, 
30-min). We used standard culture medium (RPMI-1640, 0.5% gentamicin, 1% glutamine, 1% HEPES, 0.1% 
fungizone, 10% fetal calf serum; all components from Sigma-Aldrich, Austria). Cells were first stained with 
anti-CD14 PE/FITC (BD Biosciences) to isolate monocytes. We used anti-TLR4 biotin (BD Biosciences), goat 
anti-human TLR5 (Santa Cruz Technologies), TLR4 streptavidin FITC (BD Biosciences), and TLR5 FITC donkey 
anti-goat IgG (e-Biosciences). For the staining of ErbB4, we used mouse and human ErbB4 antibodies (Santa 
Cruz Technologies) and allophycocyanin-conjugated F(ab)2 against human Fc (Jackson ImmunoReasearch) 
as described previously61. ErbB2 and ErbB3 staining was conducted by using phycoerythrin-conjugated 
anti-human ERBB2 (Fab1129P) and ERBB3 (Fab3481P) (R&D Systems)49. For flow cytometry analysis, we used 
BD LSRFortessa X-20 (BD Biosciences) and FlowJo v10. analytical software (Tree Star Inc., Ashland, OR). The 
dependent measure was mean fluorescent intensity (MFI), providing information on receptor density on the cell 
membrane.
Stimulation of TLRs and ErbB. We isolated peripheral blood mononuclear cells and seeded at 1.5 × 105 






Age (years) 26.1 (6.8) 26.2 (5.9)
Education (years) 11.0 (2.7) 10.9 (2.5)
Body mass index (BMI) 23.2 (4.1) 22.7 (4.3)
Waist-to-hip ratio 0.79 (0.12) t1: 0.79 (0.13)
Smokers/non-smokers 22/20 22/20
Positive and Negative Syndrome Scale (PANSS)
Positive symptoms 19.4 (7.9)
Negative symptoms 13.5 (7.0)
General symptoms 56.3 (17.1)
Table 1. Demographic and clinical characteristics of the participants. Data are mean (standard deviations) 
except for male/female and smokers/non-smokers ratios. There were no significant differences between 
schizophrenia patients and control subjects as revealed by t-tests (for means/SD) and chi-square tests (for 
distributions) (p > 0.2).
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stimulated for 20 hours with TLR ligands: Gram negative bacterial lipopolysaccharides (LPS) (0.5 lg/mL; TLR4) 
and flagellin from Salmonella typhimurium (2.5 lg/mL; TLR5) (InvivoGen, San Diego, CA, USA)47, 64. ErbB 
receptors were stimulated with NRG1a (296-HR, 65 amino-acid residue recombinant protein from the epider-
mal growth factor domain of NRG1a (177–241); 200 ng/ml) (R&D system Inc., Minneapolis, MN, USA)23, 25, 26. 
Following stimulation, we measured the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, and the 
anti-inflammatory cytokine IL-10 in the supernatant of monocytes by using a cytometric bead array (CBA) 
Human Inflammation kit (BD Biosciences) and FACSCanto II (BD Biosciences)64.
Data analysis. STATISTICA 13.0 (Dell Inc.) software was applied for data analysis. After Kolmogorov-Smirnov 
tests for normal distribution and Levene’s test for homogeneity of variance, analyses of variance (ANOVAs) were 
used, followed by Tukey Honestly Significant Difference (HSD) tests. Effect size values (η2) were calculated in the 
ANOVAs. The level of statistical significance was set at α < 0.05.
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